Stephan Hasmüller

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

Michael Untch, Peter A. Fasching, Gottfried E. Konecny et al. · Journal of Clinical Oncology · 2011 · 508 citations

Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer

Philipp Kiewe, Stephan Hasmüller, Steffen Kahlert et al. · Clinical Cancer Research · 2006 · 194 citations · Full text

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

Nadia Harbeck, Manfred Schmitt, Christoph Meisner et al. · European Journal of Cancer · 2013 · 163 citations

Ten-year Analysis, Breast Oncology, Medicine +9

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery

Michael Untch, Peter A. Fasching, Gottfried E. Konecny et al. · Annals of Oncology · 2011 · 133 citations

Surgical Oncology, Breast Oncology, Standard-dosed Epirubicin/cyclophosphamide +9

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis

Michael Untch, Gϋnter von Minckwitz, Gottfried E. Konecny et al. · Annals of Oncology · 2011 · 121 citations

Darbepoetin Alfa, Breast Oncology, Medicine +7